Impairment, disability, or handicap in peripheral neuropathy: analysis of the use of outcome measures in clinical trials in patients with peripheral neuropathies

Molenaar, D S; de Haan, R; Vermeulen, M
August 1995
Journal of Neurology, Neurosurgery & Psychiatry;Aug1995, Vol. 59 Issue 2, p165
Academic Journal
journal article
No abstract available.


Related Articles

  • Animal Models of Peripheral Neuropathies. Höke, Ahmet // Neurotherapeutics;Apr2012, Vol. 9 Issue 2, p262 

    Peripheral neuropathies are common neurological diseases, and various animal models have been developed to study disease pathogenesis and test potential therapeutic drugs. Three commonly studied disease models with huge public health impact are diabetic peripheral neuropathy,...

  • Chronic lymphatic leukaemia, chlorambucil, and sensorimotor peripheral neuropathy. Sandler, R.M.; Gonsalkorale, M. // British Medical Journal;11/12/1977, Vol. 2 Issue 6097, p1265 

    Reports a case on a patient with peripheral neuropathy caused by chlorambucil. Diagnosis of the patient; Types of treatment used for chlorambucil; Symptoms of peripheral neuropathy.

  • Psychometric Evaluation of Two Scales Assessing Functional Status and Peripheral Neuropathy Associated With Chemotherapy for Ovarian Cancer: A Gynecologic Oncology Group Study. Almadrones, Lois; McGuire, Deborah B.; Walczak, Janet Ruth; Florio, Colleen M.; Tian, Chunqiao // Oncology Nursing Forum;May/Jun2004, Vol. 31 Issue 3, p615 

    Purpose/Objectives: To evaluate the psychometric properties of two adapted scales, one for functional status and one for peripheral neuropathy secondary to neurotoxic chemotherapy. Design: Repeated measures methodologic design conducted within a Gynecologic Oncology Group (GOG) phase III...

  • Diabetic Peripheral Neuropathy. Flaws, Bob // Townsend Letter for Doctors & Patients;Aug/Sep2003, Issue 241/242, p172 

    Presents the study on the medical treatment of patients with diabetic peripheral neuropathy in China. Clinical signs and symptoms; Chinese medicinals administered; Effect of the medicinals to the peripheral neuropathy of the patients.

  • Clinimetric properties of a walking scale in peripheral neuropathy. Graham, R. C.; Hughes, R. A. C. // Journal of Neurology, Neurosurgery & Psychiatry;Aug2006, Vol. 77 Issue 8, p977 

    Difficulty in walking is seen in many people with peripheral neuropathies, but walking ability is not comprehensively measured by commonly used outcome measures. The clinimetric properties of the 12-Item Multiple Sclerosis Walking Scale (MSWS-12, renamed the Walk-12) were investigated in 65...

  • Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). Chhibber, A; Mefford, J; Stahl, E A; Pendergrass, S A; Baldwin, R M; Owzar, K; Li, M; Winer, E P; Hudis, C A; Zembutsu, H; Kubo, M; Nakamura, Y; McLeod, H L; Ratain, M J; Shulman, L N; Ritchie, M D; Plenge, R M; Witte, J S; Kroetz, D L // Pharmacogenomics Journal;Aug2014, Vol. 14 Issue 4, p336 

    Peripheral neuropathy is a common dose-limiting toxicity for patients treated with paclitaxel. For most individuals, there are no known risk factors that predispose patients to the adverse event, and pathogenesis for paclitaxel-induced peripheral neuropathy is unknown. Determining whether there...

  • Role of Erythropoeitin in Prevention of Chemotherapy-induced Peripheral Neuropathy. Abdelaal Kassem, M. D. Lobna; Aziz Yassin, M. D. Nadia // Pakistan Journal of Biological Sciences;2010, Vol. 13 Issue 12, p577 

    Neurotoxicity complicates the use of several commonly administered chemotherapeutic agents (platinum based alkylating agents, taxanes and vinca alkaloids), with chemotherapy-induced peripheral neuropathy being the most common manifestation. Structural damage to the peripheral nervous system...

  • α-Lipoic Acid, Diabetic Neuropathy, and Nathan's Prophecy. Papanas, N.; Maltezos, E. // Angiology;Apr2012, Vol. 63 Issue 2, p81 

    Both oral and intravenous administration of alpha-lipoic acid (ALA) has been investigated as add-on treatment for diabetic peripheral neuropathy. The recent Neurological Assessment of Thioctic Acid in Diabetic Neuropathy (NATHAN) 1 trial has shown that 4-year oral ALA administration is of some...

  • Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Peng, Ling; Ye, Xianghua; Zhou, Yun; Zhang, Junyan; Zhao, Qiong // Supportive Care in Cancer;Sep2015, Vol. 23 Issue 9, p2813 

    Background: Bortezomib is a proteasome inhibitor which has demonstrated activity against recurrent or newly diagnosed multiple myeloma (MM) and mantle cell lymphoma. Peripheral neuropathy has been described with this agent, although the overall incidence and relative risk remain unclear. We...

  • Diabetic neuropathy: Therapies for peripheral and autonomic symptoms. Emanuele, Mary Ann; Emanuele, Nicholas V. // Geriatrics;Apr97, Vol. 52 Issue 4, p40 

    Discusses pharmacologic therapies that have performed better than placebo in clinical trials involving patients with diabetic neuropathy. Pathophysiology of diabetic neuropathy; Symptoms and patient workup in peripheral neuropathy; Managing glucose and pain in peripheral neuropathy; Reason why...


Read the Article


Sign out of this library

Other Topics